MX2012007802A - Proceso para la preparacion de composiciones farmaceuticas para la liberacion sostenida de analogos de somatostanina. - Google Patents

Proceso para la preparacion de composiciones farmaceuticas para la liberacion sostenida de analogos de somatostanina.

Info

Publication number
MX2012007802A
MX2012007802A MX2012007802A MX2012007802A MX2012007802A MX 2012007802 A MX2012007802 A MX 2012007802A MX 2012007802 A MX2012007802 A MX 2012007802A MX 2012007802 A MX2012007802 A MX 2012007802A MX 2012007802 A MX2012007802 A MX 2012007802A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
preparation
sustained release
somatostatin analogs
acetic acid
Prior art date
Application number
MX2012007802A
Other languages
English (en)
Other versions
MX343112B (es
Inventor
Roland Cherif-Cheikh
Martin Montes
Thomas Ciaran Loughman
Chantal Roume
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2012007802A publication Critical patent/MX2012007802A/es
Publication of MX343112B publication Critical patent/MX343112B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de composiciones farmacéuticas inyectables para la liberación sostenida de los análogos de somatostatina y a las composiciones farmacéuticas preparadas de acuerdo con el proceso. En un aspecto preferido, el proceso comprende las etapas de combinar el acetato de lanreotida y el ácido acético, liofilizar la mezcla resultante solo una vez, e hidratar el liofilizado. El ácido acético puede ser agregado a un pH deseado durante la etapa final del proceso.
MX2012007802A 2010-01-13 2011-01-11 Proceso para la preparacion de composiciones farmaceuticas para la liberacion sostenida de analogos de somatostanina. MX343112B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29464410P 2010-01-13 2010-01-13
PCT/EP2011/000069 WO2011085957A2 (en) 2010-01-13 2011-01-11 Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs

Publications (2)

Publication Number Publication Date
MX2012007802A true MX2012007802A (es) 2012-08-31
MX343112B MX343112B (es) 2016-10-25

Family

ID=43743499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007802A MX343112B (es) 2010-01-13 2011-01-11 Proceso para la preparacion de composiciones farmaceuticas para la liberacion sostenida de analogos de somatostanina.

Country Status (24)

Country Link
US (3) US9352012B2 (es)
EP (2) EP2523653B1 (es)
JP (1) JP6029472B2 (es)
KR (1) KR101915820B1 (es)
CN (2) CN105456206B (es)
AR (1) AR079896A1 (es)
AU (1) AU2011206728B2 (es)
BR (1) BR112012017435A2 (es)
CA (1) CA2786181C (es)
DK (1) DK2523653T3 (es)
EA (1) EA023128B1 (es)
ES (1) ES2677012T3 (es)
HU (1) HUE038200T2 (es)
IL (2) IL220538A (es)
MX (1) MX343112B (es)
NZ (1) NZ600891A (es)
PL (1) PL2523653T3 (es)
PT (1) PT2523653T (es)
SG (1) SG182548A1 (es)
TR (1) TR201809874T4 (es)
TW (2) TWI536999B (es)
UA (1) UA108872C2 (es)
WO (1) WO2011085957A2 (es)
ZA (1) ZA201205160B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2523653T (pt) * 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR20160075665A (ko) 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
FR3079421B1 (fr) 2018-03-28 2024-11-15 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
RU2742196C1 (ru) * 2019-09-11 2021-02-03 Общество с ограниченной ответственностью "Медицинские нанотехнологии" Фармацевтическая композиция для приготовления инъекционного раствора при использовании в лечении магнитной гипертермии и способ ее получения
CN112791177B (zh) * 2019-10-28 2023-06-20 深圳翰宇药业股份有限公司 注射用生长抑素冻干组合物及其制备方法
EP4192427B1 (en) * 2020-08-07 2025-11-05 Pharmathen S.A. Process and apparatus for preparing viscous pharmaceutical formulations
GR1010059B (el) * 2020-08-10 2021-08-13 Φαρματεν Α.Β.Ε.Ε. Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων
LU101974B1 (en) 2020-08-07 2022-02-07 Pharmathen Sa Process and apparatus for preparing viscous pharmaceutical formulations
AU2022390573A1 (en) * 2021-11-22 2024-05-16 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085913B2 (ja) 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
RO117259B1 (ro) 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2762319A1 (fr) * 1997-04-18 1998-10-23 Pharma Biotech Microcapsules presentant une liberation prolongee et leur procede de preparation
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US6506534B1 (en) * 1999-09-02 2003-01-14 Fujitsu Limited Negative resist composition, method for the formation of resist patterns and process for the production of electronic devices
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
BRPI0314546B8 (pt) 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
US6953447B2 (en) 2002-10-22 2005-10-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) Pre-filled safety injection device with integrated waste collector
CN1415378A (zh) * 2002-10-22 2003-05-07 南京长澳医药科技有限公司 生长抑素冻干粉针及其制备工艺
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
EP2190453A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
CN102245168B (zh) 2008-12-15 2013-06-19 诺瓦提斯公司 纳米粒组合物
PT2523653T (pt) * 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina

Also Published As

Publication number Publication date
BR112012017435A2 (pt) 2020-08-25
WO2011085957A3 (en) 2012-05-03
IL220538A (en) 2016-12-29
KR101915820B1 (ko) 2018-11-06
UA108872C2 (uk) 2015-06-25
US20160339075A1 (en) 2016-11-24
PT2523653T (pt) 2018-06-28
US10206968B2 (en) 2019-02-19
EA201290637A1 (ru) 2013-01-30
CA2786181C (en) 2017-12-12
TWI536999B (zh) 2016-06-11
SG182548A1 (en) 2012-08-30
EP2523653A2 (en) 2012-11-21
EP2523653B1 (en) 2018-04-11
CN105456206A (zh) 2016-04-06
CN105456206B (zh) 2018-12-14
EP3378468A1 (en) 2018-09-26
CN102711728A (zh) 2012-10-03
CA2786181A1 (en) 2011-07-21
AR079896A1 (es) 2012-02-29
HK1222807A1 (zh) 2017-07-14
WO2011085957A2 (en) 2011-07-21
US9352012B2 (en) 2016-05-31
TW201600108A (zh) 2016-01-01
TW201129371A (en) 2011-09-01
JP2013517228A (ja) 2013-05-16
TR201809874T4 (tr) 2018-07-23
DK2523653T3 (en) 2018-07-16
MX343112B (es) 2016-10-25
US20130079282A1 (en) 2013-03-28
EA023128B1 (ru) 2016-04-29
AU2011206728A1 (en) 2012-08-30
KR20120125576A (ko) 2012-11-15
IL220538A0 (en) 2012-08-30
NZ600891A (en) 2014-05-30
PL2523653T3 (pl) 2018-09-28
AU2011206728B2 (en) 2016-02-04
ES2677012T3 (es) 2018-07-27
US20190167754A1 (en) 2019-06-06
IL248510A0 (en) 2016-12-29
HUE038200T2 (hu) 2018-09-28
ZA201205160B (en) 2013-03-27
CN102711728B (zh) 2016-01-20
JP6029472B2 (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
TW201129371A (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
AU2016219654A1 (en) Crystallization method and bioavailability
WO2011154724A3 (en) Injectable flowable composition comprising buprenorphine
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2009134383A3 (en) Vinyl substituted fatty acids
WO2010080730A3 (en) Methods and materials for delivering bile acids
PH12013500364A1 (en) Synthetic bile acid composition, method, and preparation
NZ599594A (en) Fast dissolving solid dosage form
WO2011041639A3 (en) Heteroatom containing substituted fatty acids
MY175800A (en) Combination treatment of cancer
MX2013002725A (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
WO2009118754A3 (en) A process for preparing a stable lyophilized composition
CO6362027A2 (es) Derivados de alternano
WO2012099557A3 (en) Fatty acid inhibitors
EA201170180A1 (ru) Фармацевтические композиции соматотропных гормонов
EA201101638A1 (ru) Новые твердые формы {[(2s,5r,8s,11s)-5-бензил-11-(3-гуанидинопропил)-8-изопропил-7-метил-3,6,9,12,15-пентаоксо-1,4,7,10,13-пентаазациклопентадец-2-ил]уксусной кислоты} и способы их получения
WO2008041073A8 (en) Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2011139385A3 (en) Genetic signatures in hiv-1 subtype c envelope glycoproteins
WO2010056847A3 (en) Lyophilization formulation
WO2009064155A8 (en) Immunopotentiating composition from labisia pumila extract
WO2014193969A3 (en) Compounds for the treatment of hypertension and hypertensive end stage renal disease
HK1178078B (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
UA52220U (ru) Способ стимуляции родов у самок сельскохозяйственных животных

Legal Events

Date Code Title Description
FG Grant or registration